Viatris Announces Chief Financial Officer Transition
Rhea-AI Summary
Viatris (Nasdaq: VTRS) announced that Chief Financial Officer Theodora "Doretta" Mistras will depart for a new professional opportunity; she will remain through May 22, 2026.
Paul Campbell, Chief Accounting Officer and Corporate Controller, is named interim CFO effective May 8, 2026 while a permanent successor search is conducted. Viatris will report Q1 2026 results on May 7, 2026 and host an 8:30 a.m. ET conference call.
Positive
- Interim CFO named effective May 8, 2026 to maintain continuity
- Paul Campbell has >20 years of accounting and finance experience
- Departing CFO to stay through May 22, 2026 for transition
Negative
- CFO departure creates an open permanent CFO search for investors to monitor
- Interim appointment is temporary; permanent successor timeline is unspecified
News Market Reaction – VTRS
In the May 5 session, VTRS gained 2.11%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 01 | Clinical data presentations | Positive | +0.7% | Positive Phase 3 efficacy and safety data for contraceptive patch at ACOG 2026. |
| Apr 13 | Earnings date announcement | Neutral | +2.7% | Set timing for first quarter 2026 results call on May 7, 2026. |
| Apr 10 | Clinical meeting updates | Positive | -1.0% | Multiple ophthalmology data presentations at ASCRS, including Phase 3 VEGA-3 results. |
| Mar 23 | Regulatory approval | Positive | +0.7% | Effexor SR approved in Japan for adult GAD, supported by Phase 3 data. |
| Mar 19 | Long-term strategy update | Positive | -1.8% | Outlined 2030 growth framework with revenue, EBITDA, EPS and FCF targets. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed reactions: strategic and clinical positives sometimes drew gains but occasionally saw sell-offs, indicating investors do not uniformly reward optimistic updates.
Over recent months, Viatris issued several clinically and strategically focused updates, including positive Phase 3 contraceptive data on May 1, 2026, multiple ophthalmology presentations on April 10, 2026, and Effexor approval for GAD in Japan on March 23, 2026. It also outlined a long-term growth framework on March 19, 2026. Price reactions alternated between modest gains and declines, suggesting that even constructive developments can prompt varied trading responses. Today’s CFO transition arrives against this backdrop of active pipeline and strategy communication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFO
Viatris has named Paul Campbell, currently Chief Accounting Officer and Corporate Controller, as interim Chief Financial Officer, effective May 8, 2026, while the Company conducts its search for a permanent successor. Mistras will remain with the Company until May 22, 2026, to facilitate a seamless transition.
"We thank Doretta for her significant contributions, which have helped prepare the Company to enter a period of sustainable future growth," said Scott A. Smith, CEO, Viatris. "Given Paul's deep knowledge of Viatris and his financial expertise and experience, we are confident he is the right transitional leader to maintain continuity and operational discipline while we focus on positioning the Company for sustained long-term growth."
Campbell brings more than two decades of experience in accounting, financial operations and corporate leadership to the position. In his current role as Chief Accounting Officer and Corporate Controller of Viatris, Campbell oversees the Company's global accounting and finance operations. Since joining Viatris' legacy company, Mylan, in 2002, Campbell has played a key role in strengthening financial processes, supporting strategic initiatives and maintaining disciplined financial management across the organization.
Prior to his current role, Campbell served as Mylan's Chief Accounting Officer, Senior Vice President and Controller, where he was responsible for the Company's accounting, financial operations and reporting. During his tenure, he has held positions of increasing responsibility across internal audit, business development, corporate development and operations finance, contributing to the Company's growth and transformation. Earlier in his career, Campbell spent nearly a decade at Deloitte & Touche, where he served as a Senior Manager in Audit. Campbell holds a Bachelor of Science in Accounting from Pennsylvania State University.
Viatris will release financial results for the first quarter of 2026 on May 7, 2026, and will host a conference call at 8:30 a.m. ET to discuss the results.
About Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we strive to deliver solutions that are effective at scale and built to endure. We're purpose-built to make an impact with a dynamic portfolio that spans generics, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the
Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that Mistras's significant contributions have helped prepare the company to enter a period of sustainable future growth; and that given Campbell's deep knowledge of the Company, his financial expertise and experience, we are confident he is the right transitional leader to maintain continuity and operational discipline while we focus on positioning the company for sustained long-term growth. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the possibility that the Company may not realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives and priorities; the possibility that the Company may be unable to achieve the intended or expected benefits of its enterprise-wide strategic review and related cost-saving and restructuring activities within the expected timeframe or at all; the possibility that the Company may be unable to achieve intended or expected benefits in connection with divestitures, acquisitions, strategic alliances, collaborations, or other transactions, or restructuring programs, within the expected timeframes or at all; the Company's failure to achieve expected or targeted future financial and operating performance and results; the ability to attract, motivate and retain key personnel; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with
View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-announces-chief-financial-officer-transition-302761799.html
SOURCE Viatris Inc.